Maria Luigia Randi

TL;DR: In patients with polycythemia vera, those with a hematocrit target of less than 45% had a significantly lower rate of cardiovascular death and major thrombosis than did those with an intended target of 45 to 50%.

TL;DR: In multivariable analysis, survival for the entire study cohort was adversely affected by older age, leukocytosis, venous thrombosis and abnormal karyotype; a prognostic model delineated risk groups with median survivals of 10.9–27.8 years.

TL;DR: It is concluded that JAK2 617V>F homozygosity identifies PV or ET patients with a more symptomatic myeloproliferative disorder and is associated with a higher risk of major cardiovascular events in patients with ET.

TL;DR: The 3-tiered new prognostic model, devised in an international study of 891 patients with essential thrombocythemia, outperformed conventional risk stratification in predicting future vascular events.

TL;DR: This study validates the clinical relevance of strict adherence to WHO criteria in the diagnosis of ET and provides important information on survival, disease complication rates, and prognostic factors in strictly WHO-defined ET and early/prefibrotic PMF.